Reported Saturday, Teva Pharmaceuticals Presented New Pharmacokinetic Modeling Data By Simulates Clinical Profiles Of Schizophrenia Patients Switching To UZEDY® Extended-Release Injectable Suspension At SIRS 2024
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals presented new pharmacokinetic modeling data for UZEDY, an extended-release injectable suspension for schizophrenia, at SIRS 2024. The data offers insights into dosing conversions for switching from a long-acting injectable formulation of risperidone. Additional data from the Phase 3 RISE trial reinforces UZEDY's efficacy and safety. The ADVANCE study will provide real-world findings on long-acting injectable utilization from various stakeholders.
April 08, 2024 | 7:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceuticals presented promising data on UZEDY, an extended-release injectable for schizophrenia, including dosing strategies and efficacy/safety profiles from the RISE trial.
The presentation of new pharmacokinetic modeling data and positive results from the Phase 3 RISE trial for UZEDY by Teva Pharmaceuticals at SIRS 2024 could positively impact investor sentiment. The data supports UZEDY's efficacy and safety, potentially leading to increased adoption and revenue for Teva. The real-world findings from the ADVANCE study could further validate UZEDY's market position.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90